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MaBACKGROUND Vitamin K–dependent factors protect against vascular and renovascular calciﬁcation, and vitamin K
antagonists may be associated with a decreased glomerular ﬁltration rate (GFR).
OBJECTIVES This study analyzed changes in GFR during long-term treatment with warfarin or dabigatran etexilate
(DE) in patients enrolled in the RE-LY (Randomized Evaluation of Long Term Anticoagulation Therapy) trial.
METHODS Of the 18,113 patients in the RE-LY study randomized to receive DE (110 mg or 150 mg twice daily) or
warfarin, 16,490 patients with atrial ﬁbrillation had creatinine values measured at baseline and at least 1 follow-up visit.
Changes in GFR for up to 30 months were evaluated.
RESULTS GFR declined in all treatment groups. After an average of 30 months, the mean  SE decline in GFR was
signiﬁcantly greater with warfarin (–3.68  0.24 ml/min) compared with DE 110 mg (–2.57  0.24 ml/min; p ¼ 0.0009
vs. warfarin) and DE 150 mg (–2.46  0.23 ml/min; p ¼ 0.0002 vs. warfarin). A decrease in GFR >25% was less likely
with DE 110 mg (hazard ratio: 0.81 [95% conﬁdence interval: 0.69 to 0.96]; p ¼ 0.017) or DE 150 mg (hazard ratio: 0.79
[95% conﬁdence interval: 0.68 to 0.93]; p ¼ 0.0056) than with warfarin in the observation period >18 months. Patients
with poor international normalized ratio control (i.e., time in therapeutic range <65%) exhibited a faster decline in GFR. A
more pronounced decline in GFR was associated with previous warfarin use and with the presence of diabetes.
CONCLUSIONS Patients with atrial ﬁbrillation receiving oral anticoagulation exhibited a decline in renal function that
was greater in those taking warfarin versus DE, and it was ampliﬁed by diabetes and previous vitamin K antagonist use.
(Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY] With Dabigatran Etexilate; NCT00262600)
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
CKD-EPI = Chronic Kidney
Disease Epidemiology
Collaboration
DE = dabigatran etexilate
GFR = glomerular ﬁltration
rate
INR = international normalized
ratio
SCr = serum creatinine
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2483V itamin K is a hemostatic factor involved inphysiological regulations beyond coagula-tion, including soft tissue calciﬁcation, cell
growth, and apoptosis resulting in structural damage
to the kidney vasculature (1). Atherosclerotic pro-
cesses and vascular calciﬁcation are closely linked to
the vitamin K–dependent protein matrix gamma-
carboxyglutamic acid. This residue is an inhibitor of
calciﬁcation, the deletion of which can produce
arterial media sclerosis (2). Vitamin K antagonists
(VKAs) are associated with increased calciﬁcation of
renal and other arteries (1,2). Oral anticoagulationSEE PAGE 2494
FIGURE 1 Flow Diagram of Patient Selection and Treatment Allocation
20,377 patients
screened
18,113 randomized
16,490 patients
analyzed
Warfarin sodium, adjusted dose (n=5,594)
Dabigatran etexilate 110 mg twice daily (n=5,472)
Dabigatran etexilate 110 mg twice daily (n=5,424)
Creatinine values not available at baseline
and at least at one post-baseline visit (n=1,623)
Trial Allocation
TTR = time in therapeutic
range
= vitamin K antagonist(s)with VKAs has been shown to accelerate pre-existing
vascular calciﬁcations, whereas vitamin K substitution
has been shown to improve these processes (3,4). VKA
use is reportedly associated with increased coronary
plaque load (5) and unstable plaque morphology (1).
The possibility exists, therefore, that VKA treatment
accelerates vascular end-organ damage, including
renal dysfunction. In dialysis patients with low
vitamin K levels, these mechanisms are regarded as
one pathophysiologic mechanism for poor cardiovas-
cular outcome (6,7). By contrast, thrombin antagonists
such as dabigatran etexilate (DE) (8) and melagatran
(9) have been shown to reduce advanced atheroscle-
rotic plaque burden and improve endothelial function
in animal models of atherosclerosis (8).
The RE-LY (Randomized Evaluation of Long Term
Anticoagulation Therapy) trial database provides a
unique opportunity to directly assess renal function
during treatment with a VKA or a thrombin inhibitor
in a moderate- to high-risk population with atrial
ﬁbrillation (AF). The present analysis compared
changes in renal function in patients with AF who
were assigned to receive either DE or warfarin in the
RE-LY trial.
METHODS
The design, patient characteristics, and outcomes of
the RE-LY trial have been published previously (10,11).
The study was conducted in 967 centers in 44 coun-
tries. Patients with AF who had at least 1 additional
risk factor for stroke were randomized in a 1:1:1 allo-
cation ratio to receive DE in a blinded fashion in ﬁxed
doses of 110 mg twice daily (DE 110) or 150 mg twice
daily (DE 150) or adjusted doses of warfarin (target
international normalization ratio [INR]: 2.0 to 3.0) in
an unblinded fashion for a median of 2 years. There
was a balanced recruitment of patients previously
treated with a VKA (VKA-experienced patients) and
patients who had not been previously treated with aVKA (VKA-naive patients). All patients were
randomized to treatment by using a central
randomization service with an interactive
voice response system located at the Popula-
tion Health Research Institute in Hamilton,
Ontario, Canada. Patients with an estimated
glomerular ﬁltration rate (GFR) #30 ml/min
(according to the Cockcroft-Gault formula)
were excluded per the protocol. Nevertheless,
90 patients with lower renal function were
included.
Between December 2005 and December
2007, a total of 18,113 patients were random-
ized to receive DE 110 (5,983 treated), DE 150
(6,059 treated), or warfarin sodium (5,998
treated) (Figure 1). The study close-out was between
December 2008 and March 2009. Measurement of
serum creatinine (SCr) was planned at baseline; at 3,
6, and 12 months; and annually thereafter. Values
were available at baseline and at least 1 post-baseline
visit in 16,490 patients (n ¼ 5,424 for DE 110; n ¼ 5,472
for DE 150; and n ¼ 5,594 for warfarin). For safety
reasons, additional renal function testing was
allowed during the study at any time; the results from
these local tests, however, were not considered in
this analysis. Patients taking DE who were found to
have a reduced creatinine clearance (<30 ml/min)
during the trial had their treatment stopped until the
level increased to >30 ml/min. In cases in which the
creatinine clearance level remained <30 ml/min a
second time, DE was permanently discontinued for
the duration of the trial, but respective patients were
followed up until the trial was completed.
VKA
TABLE 1 Demographic Characteristics and Baseline Values
DE 110 mg BID
(n ¼ 5,424)
DE 150 mg BID
(n ¼ 5,472)
Warfarin
(n ¼ 5,594)
Age, yrs 71.3  8.6 71.3  8.8 71.5  8.5
Body mass index, kg/m2 28.8  5.8 28.8  5.7 28.8  5.7
Male 65.4 63.9 63.9
Region
Asia 14.9 15.1 15.4
Central Europe 11.7 11.5 11.7
Western Europe 25.3 25.5 25.3
Latin America 5.4 5.4 5.2
United States, Canada 36.9 37.0 36.7
Other 5.7 5.6 5.7
AF type
Paroxysmal 32.0 32.7 33.5
Permanent 35.3 35.7 34.1
Persistent 32.6 31.6 32.4
CHADS2 score
0–1 32.9 32.6 31.4
2 34.9 35.3 36.7
3–6 32.2 32.1 32.0
GFR (CKD-EPI) 65.8  16.7 65.8  17.0 66.0  16.5
CKD stages
1 ($90 ml/min) 7.5 8.1 7.2
2 (60 to <90 ml/min) 55.4 53.9 55.6
3 (30 to <60 ml/min) 36.2 37.1 36.4
4–5 (<30 ml/min) 0.9 0.8 0.7
History of stroke/SEE/TIA 21.6 22.5 21.6
History of myocardial infarction 16.2 16.9 15.9
History of heart failure 31.8 31.8 31.5
Documented coronary artery disease 27.3 28.0 27.5
Hypertension requiring medical treatment 78.8 78.8 78.6
History of diabetes mellitus 23.5 22.8 23.2
Continued on the next page
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2484Individual observation periods ranged between
12 and 37 months. Patients were subdivided into 3
groups depending on their time of recruitment and
their resulting ability to have the last SCr measure-
ment recorded at 12 and 24 months after randomiza-
tion or later. The majority of measurements beyond
24 months occurred at w30 months. Measurements
were allocated to time points according to the
following schedule: 3 months, <137 days; 6 months,
137 to 273 days; 12 months, 274 to 547 days; 24
months, 548 to 821 days; and 30 months, $822 days.
If >1 value per time window was available, the value
closest to the center of the respective interval was
selected for analysis.
MEASUREMENT OF RENAL FUNCTION. Venous blood
was drawn at randomization, before initiation of
study treatment, and at all visits that included a
protocol-driven SCr assessment. The blood was
centrifuged within 30 min at 2,000 g for 10 min. The
tubes were thereafter immediately frozen at –20C
or colder. Aliquots were stored centrally at –70C
to allow for batch analysis. Plasma creatininemeasurements were performed in a core laboratory
by using a Roche Modular analyzer with a kinetic
colorimetric compensated Jaffe assay (Roche
Modular, Meylan, France).
GFR was estimated from SCr (12,13), and the fol-
lowing equations were used. Cockcroft-Gault equa-
tion: GFR [ml/min] ¼ ([140 – age (years)]  [weight
(kg)]  0.85 [if female]/[72  SCr (mg/dl)]); Chronic
Kidney Disease Epidemiology Collaboration [CKD-EPI]
equation: GFR ¼ 141  min (SCr [mg/dl]/k,1)a 
max (SCr [mg/dl]/k, 1)–1.209  0.993age [years]  1.018
(if female)  1.159 (if black), in which k is 0.7 for
female subjects and 0.9 for male subjects, and a
is –0.329 for female subjects and –0.411 for male sub-
jects. For sensitivity analyses, GFR was also estimated
according to the Modiﬁcation of Diet in Renal Disease
equation by using the following formula: GFR
[ml/min] ¼ 186  SCr [mg/dl]–1.154  age [years]–0.203 
1.21 (if black)  0.742 (if female). Estimation of GFR
with the CKD-EPI equation produced the smallest
variation (coefﬁcient of variationw25%), whereas the
Cockcroft-Gault formula produced the highest (coef-
ﬁcient of variation w37%). Because the most precise
estimation of renal function and the related changes
seemed to occur with CKD-EPI, the results regarding
renal function decline are given for GFR determined by
using this equation.
STATISTICAL ANALYSIS. This study was a post-hoc
analysis. Continuous variables at baseline are pre-
sented as mean  SD, with between-group compari-
sons tested by using an analysis of variance. Adjusted
means (i.e., estimates resulting from model-based
analyses) are reported together with respective SEs.
Categorical variables are presented as percentages
and were compared by using chi-square tests.
Mean changes from baseline over time were
analyzed by using a restricted maximum likelihood–
based repeated measures approach (14). Analyses
included the ﬁxed effects of treatment, time point,
time of recruitment (early, intermediate, or late;
determining the ability to reach the 12-, 24-, or
30-month visit), and treatment-by-time-point inter-
action, as well as the continuous, ﬁxed covariates of
baseline and baseline-by-time-point interaction. An
unstructured (co)variance was used to model the
within-patient measurements, and the Kenward-
Roger approximation was used to estimate the de-
nominator degrees of freedom. To protect against
spurious ﬁndings, we implemented the following
procedure for the comparison of treatment groups: in
case of a signiﬁcant treatment-by-time interaction
(an alpha level of 0.05), homogeneity of treatments
at each time point was tested at an alpha level of
TABLE 1 Continued
DE 110 mg BID
(n ¼ 5,424)
DE 150 mg BID
(n ¼ 5,472)
Warfarin
(n ¼ 5,594)
Previous VKA use (stratiﬁed randomization)
Naive 49.5 49.5 50.5
Experienced 50.5 50.5 49.5
Duration of previous use of VKA, months
Median 3.0 3.0 2.0
Q1–Q3 0.0–30.0 0.0–31.0 0.0–28.0
Smoking
Ex-smoker 44.4 43.9 43.4
Nonsmoker 48.2 48.5 49.2
Smoker 7.4 7.6 7.4
Alcohol consumption 34.1 33.6 33.5
Normal study termination 91.7 91.7 90.5
Concomitant medication (>10%)
Beta-blocker 63.4 64.1 62.0
Diuretic 50.5 51.2 50.7
ACE inhibitors 45.2 45.4 44.2
Statin 45.4 44.5 44.8
ASA 39.8 38.8 40.3
Calcium-channel blocker 33.0 32.1 32.6
Digoxin 29.6 28.5 29.4
P-gp inhibitor 24.3 24.2 24.2
ARBs 24.2 24.2 23.8
Vitamins 22.0 21.6 20.6
Oral hypoglycemic 17.0 16.7 16.5
Proton pump inhibitor 14.3 14.0 13.8
Alpha-blocker/other vasodilator 13.1 13.0 13.4
Amiodarone 10.5 11.0 10.6
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; ARBs ¼ angiotensin receptor blockers; ASA ¼
aspirin; BID¼ twice daily; CHADS2 ¼ congestive heart failure, hypertension, age$75 years, diabetes mellitus, and
stroke/TIA; CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration; DE ¼ dabigatran etexilate; GFR ¼
glomerular ﬁltration rate; P-gp ¼ P-glycoprotein 1; Q ¼ quartile; SEE ¼ systemic embolic event; TIA ¼ transient
ischemic attack; VKA ¼ vitamin K antagonist.
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24850.01 (Bonferroni correction to adjust for multiplicity);
in all analyses in which the 2 DE doses were evaluated
individually at time points when treatments were
signiﬁcantly heterogeneous, the 2 doses were tested
against warfarin at an alpha level of 0.01/2 ¼ 0.005.
Subgroup analyses were performed for diabetes
and previous use of VKA treatment. In addition,
as a form of sensitivity analysis, the time to ﬁrst
substantial deterioration of renal function was deter-
mined for each patient, deﬁned as a reduction in GFR
by at least 25% (ﬁrst RIFLE criterion); this cutoff was
deliberately used although it was developed by using
data from patients with acute kidney injury (15). A
similar analysis was performed by using a 30% decline
in GFR because this decline within 2 to 3 years was
shown to be predictive of end-stage renal disease
occurring later (16,17). These data were analyzed by
applying Cox regression with a separation of time on
treatment, using a cutoff of 18 months. All analyses
were performed by using SAS version 9.2 (SAS Insti-
tute, Inc., Cary, North Carolina).
RESULTS
BASELINE CHARACTERISTICS. Baseline characteris-
tics for the DE groups and warfarin are displayed in
Table 1. Baseline characteristics were similar between
patients recruited early, during the intermediate
phase, or late into the trial, which determined ability
to reach visits at 24 or 30 months. The risk proﬁles of
patients were comparable, independent of whether
they were recruited early or late. Online Table 1
summarizes the baseline renal parameters in the 3
treatment arms. Renal parameters at baseline were
similar among the treatment groups and did not differ
when patients were grouped according to their time of
recruitment. Moderate renal impairment (creatinine
clearance according to the Cockcroft-Gault formula of
30 to <50 ml/min) was present at baseline in 18.6% of
all patients, 36.6% who were in chronic kidney disease
stage 3 (based on the CKD-EPI equation).
GFR CHANGES FROM BASELINE OVER TIME. A
continuous decline in kidney function was observed
in the total patient population. Table 2 displays the
adjusted changes from baseline in GFR (based on the
CKD-EPI equation), using the model for repeated
measurements as described in the Methods but
without any treatment-related factors. From the
mean reductions at each time point, respective
annual reductions were calculated. The calculated
annual rate of decline was larger when only the early
measurements were considered but was less apparent
when the complete time span was taken into
consideration. The decline was more prominent inpatients with previous VKA use (especially in the
beginning of the trial) and in patients with diabetes
(especially toward the end of the trial). It is also
noteworthy that the baseline values were lower in
patients with previous VKA use compared with those
who were treatment naive and in patients with dia-
betes versus those without diabetes. Previous VKA
use was part of the randomization strategy (10).
GFR CHANGES FROM BASELINE OVER TIME ACCORDING
TO TREATMENT GROUP. Table 3 and Figure 2 summa-
rize the main results of GFR changes from baseline
according to treatment group. There was a signiﬁcant
treatment-by-time-point interaction (p < 0.0001),
indicating that there were differences between
treatment groups which differed between time
points. Early after 3 months, the greater decrease in
GFR with both DE doses was nominally (at a p < 0.05
level) statistically signiﬁcant for DE 150 versus
warfarin (p ¼ 0.022), although it did not maintain
signiﬁcance after Bonferroni correction. Although
TABLE 2 Mean Baseline Values of Estimated GFR (CKD-EPI) and Adjusted* Mean Changes From Baseline in All Patients and
According to Previous VKA Use and Diabetes Status
All Patients
Previous VKA Use Diabetes
No Yes No Yes
Baseline
N 16,490 8,219 8,269 12,672 3,818
Mean  SE 65.87  0.13 66.13  0.18 65.61  0.18 66.34  0.15 64.33  0.29
3 months
N 15,544 7,717 7,825 11,973 3,571
Adjusted mean  SE change from baseline –0.97  0.08 –0.64  0.11 –1.29  0.10 -0.97  0.09 -0.99  0.17
p Value (vs. previous time point) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Calculated annual decline, mean  SE –3.89  0.31 –2.56  0.46 –5.18  0.41 –3.87  0.35 –3.95  0.66
6 months
N 15,151 7,496 7,654 11,663 3,488
Adjusted mean  SE change from baseline –1.18  0.08 –1.10  0.12 –1.25  0.11 –1.11  0.09 –1.38  0.18
p Value (vs. previous time point) 0.0084 < 0.0001 0.64 0.084 0.025
Calculated annual decline, mean  SE –2.35  0.17 –2.20  0.25 –4.98  0.22 –2.23  0.18 –2.76  0.37
12 months
N 14,277 6,986 7,290 11,022 3,255
Adjusted mean  SE change from baseline –1.87  0.09 –1.66  0.13 –2.06  0.14 –1.73  0.10 –2.34  0.20
p Value (vs. previous time point) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Calculated annual decline, mean  SE –1.87  0.09 –1.66  0.13 –2.06  0.14 –1.73  0.10 –2.34  0.20
24 months
N 10,321 4,934 5,386 7,998 2,323
Adjusted mean  SE change from baseline –2.60  0.11 –2.18  0.16 –2.98  0.14 –2.31  0.12 –3.56  0.23
p Value (vs. previous time point) <0.0001 0.0003 <0.0001 <0.0001 <0.0001
Calculated annual decline, mean  SE –1.30  0.05 –1.09  0.08 –1.49  0.07 –1.16  0.06 –1.78  0.12
30 months
N 5,060 1,859 3,200 3,905 1,155
Adjusted mean  SE change from baseline –2.91  0.14 –2.52  0.22 –3.24  0.22 –2.53  0.15 –4.27  0.30
p Value (vs. previous time point) 0.014 0.10 0.11 0.13 0.0091
Calculated annual decline, mean  SE –1.16  0.05 –1.01  0.09 –1.30  0.07 –1.01  0.06 –1.71  0.12
*Statistical model includes continuous baseline, month, baseline-by-month interaction, and patient cohort (early, intermediate, and late recruitment).
Abbreviations as in Table 1.
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2486there were similar reductions between the treatment
arms after 6 and 12 months, the reductions with DE
treatments were smaller after 30 months compared
with warfarin (DE 110: –2.57 [p ¼ 0.0009 vs. warfarin];
DE 150: –2.46 [p ¼ 0.0002 vs. warfarin]; and warfarin:
–3.68). These results were conﬁrmed in sensitivity
analyses: 1) including only patients who did not dis-
continue the study early (91.3%); 2) including only
patients who were recruited early and were therefore
able to reach the 30-month visit; and 3) by using
multiple imputation and “simple” analysis of covari-
ance models according to time point. The results in
those patients recruited early and who were able to
reach the 30-month visit were similar and are sum-
marized in Table 4 (Online Figure 1). The results were
also conﬁrmed when at least 2, 3, 4, or 5 GFR values
required during follow-up were available for analysis
or when the Modiﬁcation of Diet in Renal Disease
equation was used for estimation of GFR.
A multivariate model that included age, sex,
ethnicity, region, smoking, alcohol consumption, AFtype, pre-treatment with VKA, history of diabetes,
stroke/systemic embolic event/transient ischemic
attack, hypertension, coronary artery disease, heart
failure, myocardial infarction, and the most frequent
co-medications (Table 1) as additional explanatory
variables determined virtually the same results with
regard to differences between treatment groups.
Among the explanatory variables, age, sex, history of
myocardial infarction, previous VKA use, and co-
medication with angiotensin receptor blockers,
amiodarone, or diuretics had the strongest impact on
changes in GFR (p < 0.0001 for all). In addition, the
intention-to-treat analysis including all available
data, whether on or off study medication, produced
similar results. At 30 months, the decline in the group
randomized to receive warfarin (–3.65) was signiﬁ-
cantly greater than in both DE groups (DE 110: –2.69,
p ¼ 0.0032; DE 150: –2.62, p ¼ 0.0014). To address the
potential concern that patients in the 2 DE groups had
stopped the trial early due to greater renal function
deterioration (and therefore a positive selection is
TABLE 3 Mean Baseline Values of Estimated GFR (CKD-EPI) and Adjusted* Mean Changes
From Baseline by Treatment
DE 110 mg BID DE 150 mg BID Warfarin
Baseline
N 5,424 5,472 5,594
Mean  SE 65.81  0.23 65.77  0.23 66.04  0.22
3 months
N 5,130 5,171 5,243
Adjusted mean  SE change from baseline –1.01  0.13 –1.17  0.14 –0.74  0.13
Difference vs. warfarin, mean  SE –0.27  0.19 –0.43  0.19
p Value 0.15 0.022
6 months
N 5,000 5,005 5,146
Adjusted mean  SE change from baseline –1.08  0.14 –1.35  0.14 –1.10  0.14
Difference vs. warfarin, mean  SE 0.02  0.20 –0.26  0.20
p Value 0.93 0.21
12 months
N 4,686 4,696 4,895
Adjusted mean  SE change from baseline –1.84  0.15 –1.82  0.15 –1.94  0.15
Difference vs. warfarin, mean  SE 0.10 0.22 0.12  0.22
p Value 0.63 0.59
24 months
N 3,368 3,434 3,519
Adjusted mean  SE change from baseline –2.51  0.18 –2.31  0.18 –2.96  0.18
Difference vs. warfarin, mean  SE 0.45  0.26 0.65  0.26
p Value 0.081 0.011
30 months
N 1,672 1,685 1,703
Adjusted mean  SE change from baseline –2.57  0.24 –2.46  0.23 –3.68  0.24
Difference vs. warfarin, mean  SE 1.11  0.33 1.22  0.33
p Value 0.0009 0.0002
The p value for treatment-by-month interaction was <0.0001. The p values for test of treatment differences
according to month were: 0.068 (3 months), 0.32 (6 months), 0.84 (12 months), 0.035 (24 months), and
0.0003 (30 months). Signiﬁcant p values (after adjustment for multiplicity of testing) are given in bold.
*Statistical model includes treatment, continuous baseline, month, baseline-by-month interaction, treatment-
by-month interaction, and patient cohort (early, intermediate, and late recruitment).
Abbreviations as in Table 1.
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2487responsible for the better outcomes at later time
points), the mean baseline, last value, and change
from baseline were evaluated for CKD-EPI, creatinine
clearance, and SCr in all patients with early study
termination. No major differences were seen between
treatment groups. The number of patients with
creatinine clearance <30 ml/min at the time of stop-
ping totaled 22, 34, and 25 in the 3 treatment groups,
respectively. These numbers are comparable and are
not high enough to explain the differences between
treatments.
GFR CHANGES FROM BASELINE OVER TIME ACCORDING
TO LEVEL OF INR CONTROL. Figure 3 (left panel) dis-
plays GFR changes in the DE groups compared with
warfarin at different levels of INR control. Patients on
warfarin who were in the therapeutic range (INR 2.0
to 3.0) for <65% of the time had a signiﬁcantly larger
decline in GFR at 24 and 30 months compared with
those receiving both DE doses (p < 0.005 for all). To
explore whether this ﬁnding is related to vitamin K
antagonism, we divided the warfarin group into 4
subgroups. Information on INR was missing for 24
patients (0.4%). The 4 subgroups were: 1) patients
with “excellent” INR control (time in therapeutic
range [TTR] $80%, n ¼ 1,236 [22.1%]); 2) patients with
“good” INR control (TTR $65% to <80%, n ¼ 1,889
[33.8%]); 3) patients with “poor” INR control
(TTR <65%) and INR predominantly below the ther-
apeutic range (TTR <65%, n ¼ 1,725 [30.8%]); and 4)
patients with “poor” INR control and INR predomi-
nantly above the therapeutic range (n ¼ 720 [12.9%]).
Both DE doses were associated with smaller GFR re-
ductions that were signiﬁcant at 12 and 24 months
compared with the group of overdosed warfarin pa-
tients (i.e., those at an INR level predominantly above
the therapeutic range [INR mainly >3.0]; p < 0.005
for all) (Figure 3, right panel). Patients who were
overdosed with warfarin had a more prominent
decline in GFR than those in the targeted range or
those undertreated (INR mainly <2.0) with warfarin
(Figure 4). These differences regarding the INR con-
trol levels were not observed for absolute doses of
warfarin taken (not shown).
GFR CHANGES FROM BASELINE OVER TIME ACCORDING
TO DIABETES STATUS. We determined whether sub-
jects with a high risk of progressive decline in renal
function, such as patients with diabetes, experienced
differential effects with DE or warfarin. Because only
minor differences were observed between the 2 DE
doses in the main analysis, all patients assigned to DE
were pooled. Figure 5 depicts the decline in patients
with and without diabetes. In general, patients with
diabetes had lower GFR levels at baseline compared
with nondiabetic subjects (64.3 vs. 66.3 ml/min,p < 0.0001; 64.0 vs. 66.4 ml/min, p < 0.0001 [after
adjustment]) and had amore pronounced GFR decline.
At 30 months, the decline in GFR in patients with dia-
beteswas signiﬁcantly greaterwithwarfarin compared
with DE (p < 0.005).
GFR CHANGES FROM BASELINE OVER TIME ACCORDING
TO PREVIOUS USE OF VKA. VKA-experienced patients
had slightly lower GFR values at baseline compared
with VKA-naive patients (65.6 vs. 66.1 ml/min;
p ¼ 0.046), but after adjustment, this difference
vanished (65.8 vs. 65.9 ml/min; p ¼ 0.69). Figure 6
depicts the decline in VKA-experienced and VKA-
naive patients over time. In general, experienced pa-
tients had a more pronounced GFR decline than naive
patients. In the ﬁrst year, there was little difference
between DE and warfarin in either subgroup. Later,
however, patients taking DE had a smaller GFR
reduction (difference compared with warfarin in
VKA-naive patients at 24 months: 1.03 [p ¼ 0.0011];
FIGURE 2 Estimated GFR (CKD-EPI) Over Time
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Data are shown (left) unadjusted and (right) fully adjusted for age, sex, ethnicity regions, smoking, alcohol consumption, atrial ﬁbrillation type,
history of diabetes, stroke, embolism, transient ischemic attack, hypertension, coronary artery disease, heart failure, myocardial infarction,
previous vitamin K antagonist use, and most frequent concomitant medications. bid ¼ twice daily; CKD-EPI ¼ Chronic Kidney Disease Epidemi-
ology Collaboration; DE ¼ dabigatran etexilate.
TABLE 4 Mean Baseline Values of Estimated GFR (CKD-EPI) and Adjusted* Mean Changes
From Baseline by Treatment, Analysis Including Only Patients Who Were Recruited Early
and Were Therefore Able to Reach the 30-Month Visit
DE 110 mg BID DE 150 mg BID Warfarin
Baseline
N 2,257 2,277 2,311
Mean  SE 65.53  0.35 65.08  0.35 65.46  0.33
3 months
N 2,089 2,111 2,138
Adjusted mean  SE change from baseline –0.98  0.20 –1.00  0.20 –0.52  0.20
Difference to warfarin, mean  SE –0.46  0.29 –0.48  0.29
p Value 0.11 0.094
6 months
N 2,080 2,059 2,125
Adjusted mean  SE change from baseline –0.34  0.21 –0.61  0.21 –0.49  0.22
Difference to warfarin, mean  SE 0.15  0.30 –0.11  0.30
p Value 0.62 0.70
12 months
N 2,020 2,010 2,096
Adjusted mean  SE change from baseline –1.90  0.22 –2.01  0.23 –1.77  0.22
Difference to warfarin, mean  SE –0.13  0.31 –0.24  0.32
p Value 0.69 0.45
24 months
N 1,669 1,668 1,718
Adjusted mean  SE change from baseline –2.69  0.26 –2.76  0.26 –3.28  0.26
Difference to warfarin, mean  SE 0.59  0.37 0.52  0.37
p Value 0.11 0.16
30 months
N 1,672 1,685 1,703
Adjusted mean  SE change from baseline –2.53  0.27 –2.55  0.26 –3.66  0.27
Difference to warfarin, mean  SE 1.12  0.38 1.10  0.37
p Value 0.0029 0.0032
*Statistical model includes treatment, continuous baseline, month, baseline-by-month interaction, treatment-by-
month interaction. The p value for treatment-by-month interaction was 0.0006. The p values for test of treat-
ment differences according to month were: 0.16 (3 months), 0.67 (6 months), 0.75 (12 months), 0.22 (24 months),
and 0.0031 (30 months). Signiﬁcant p values (after adjustment for multiplicity of testing) are given in bold.
Abbreviations as in Table 1.
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2488difference compared with warfarin in VKA-
experienced patients at 30 months: 1.07 [p ¼ 0.0035]).
TIME TO FIRST SUBSTANTIAL DETERIORATION IN
RENAL FUNCTION. The rates of substantial deterio-
ration in renal function (>25% decline in CKD-EPI) by
time were investigated for the 3 treatment groups.
Cox regression analysis with study period (initial 18
months vs. later) as an additional factor conﬁrmed
higher deterioration rates in the second half of the
trial with warfarin. For the treatment-by-period
interaction, the resulting p value was 0.038, indi-
cating that there may be a differential treatment
effect in both study periods. Although no treatment
differences were seen in the ﬁrst 18 months, there
was an advantage of both DE doses over warfarin later
in the period (hazard ratio: 0.81 [95% conﬁdence
interval (CI): 0.69 to 0.96]; p ¼ 0.017 for DE110 vs.
warfarin; hazard ratio: 0.79 [95% CI: 0.68 to 0.93];
p ¼ 0.0056 for DE150 vs. warfarin). A cutoff of 25%
was chosen, which refers to an established RIFLE
criterion (15) for acute kidney failure. Because a
decline in GFR over 2 to 3 years is reportedly predic-
tive of the development of end-stage renal disease, a
cutoff of 30% was also investigated (16,17). After
18 months, the decline in GFR was less for DE
110 (hazard ratio: 0.75 [95% CI: 0.62 to 0.92];
p ¼ 0.00052), and DE 150 (hazard ratio: 0.66 [95% CI:
0.54 to 0.81]; p # 0.0001) compared with warfarin.
DISCUSSION
Comparing DE 110 and DE 150 versus warfarin in this
post-hoc analysis from the RELY trial, a signiﬁcant
treatment-by-time interaction was observed, with a
FIGURE 3 Estimated GFR (CKD-EPI) Over Time by INR Control
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Data are shown (left) unadjusted and (right) fully adjusted for age, sex, ethnicity regions, smoking, alcohol consumption, atrial ﬁbrillation type,
history of diabetes, stroke, embolism, transient ischemic attack, hypertension, coronary artery disease, heart failure, myocardial infarction,
previous vitamin K antagonist use, and most frequent concomitant medications. INR ¼ international normalized ratio (target range 2.0–3.0);
War ¼ warfarin; other abbreviations as in Figure 2.
FIGURE 4 Estimated GFR (CKD-EPI) Over Time by INR Control in Patients on Warfarin
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Data adjusted for age, sex, ethnicity regions, smoking, alcohol consumption, atrial ﬁbril-
lation type, history of diabetes, stroke, embolism, transient ischemic attack, hypertension,
coronary artery disease, heart failure, myocardial infarction, previous vitamin K antagonist
use, and most frequent concomitant medications. eGFR ¼ estimated glomerular ﬁltration
rate; other abbreviations as in Figures 2 and 3.
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2489trend toward a larger earlier decline in renal function
with DE (150-mg dose only) and a larger late decline
with warfarin. The decline in GFR as determined by
using the CKD-EPI equation was limited tow1 ml/min
per year, although this outcome wasmore pronounced
with warfarin than with DE at 30 months. Patients
outside the therapeutic range of INR control (in
particular those with high INR levels) and those with
previous VKA treatment had a more pronounced
decline, with a signiﬁcantly greater reduction in GFR
compared with either DE dose from 6 months onward.
The GFR decline in patients with diabetes was more
pronounced than in those without diabetes, whereas
the difference between the warfarin and DE groups
was consistent with the overall group. A continuous
decline in kidney function was observed in an elderly
population with AF, and the decline was most pro-
nounced in those with diabetes (18). Compared with
previous reports of annual declines in GFR in an aging
population, the results observed in our analysis
(annual decline of –1.15 ml/min in CKD-EPI in the
overall population and –1.71 ml/min in patients with
diabetes) are in agreement with these previous reports
in elderly patients. This decline in renal function must
be taken into consideration when administering
drugs, such as DE, that are cleared by the kidney;
dosing of these medications may need adjustment or
treatment should be discontinued if severe renal
impairment develops.
Patients with renal impairment are often high-risk
cardiovascular patients with a higher prevalence ofAF (19–21). Among these patients, thromboembolic
complications are more prevalent than in patients
with nonvalvular AF and normal renal function
(22–24). When renal function is impaired, there is
a variable and often clinically relevant decline in
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FIGURE 5 Estimated GFR (CKD-EPI) Over Time by Diabetes Status
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Data adjusted for age, sex, ethnicity regions, smoking, alcohol consumption, atrial ﬁbril-
lation type, history of diabetes, stroke, embolism, transient ischemic attack, hypertension,
coronary artery disease, heart failure, myocardial infarction, previous vitamin K antagonist
use, and most frequent concomitant medications. No ¼ no diabetes; Yes ¼ diabetes;
other abbreviations as in Figure 2.
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2490renal function (25) involving vascular mechanisms
such as oxidative stress and inﬂammation and vas-
cular calciﬁcations, which in turn increase adverse
cardiovascular outcomes (26). In AF, VKAs have beened GFR (CKD-EPI) Over Time by Previous VKA Use
nced Warfarin - Experienced
DE 150 - Naïve Warfarin - Naïve
DE 150 - Experienced
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e, sex, ethnicity regions, smoking, alcohol consumption, atrial ﬁbril-
f diabetes, stroke, embolism, transient ischemic attack, hypertension,
se, heart failure, myocardial infarction, previous vitamin K antagonist
frequent concomitant medications; abbreviations as in Figure 2.widely recommended for anticoagulation in patients
with and without renal impairment (27), although
many trials excluded patients with severe renal
impairment (22,24). Interestingly, warfarin has been
associated with biopsy-proven nephropathy in pa-
tients with and without renal impairment, which is
related to increased mortality (28). These ﬁndings are
in agreement with animal studies showing induction
of nephropathy with high doses of warfarin (29,30).
The randomized controlled trials comparing
warfarin with novel anticoagulants such as DE (11)
provide a unique opportunity to compare potential
differential effects on the decline in renal function
associated with VKAs and the novel thrombin antag-
onist DE. Consistent with previous observations
reporting a decline in renal function with warfarin
depending on the INR of therapeutic range (28), we
found that DE treatment was associated with a
smaller decline in renal function over time compared
with warfarin. In agreement with previous studies
(31), patients on warfarin exhibiting INR values
mainly above the therapeutic range, or those who
were VKA experienced, had a more prominent decline
in GFR according to the estimation with CKD-EPI, the
most precise predictor of renal function decline. The
small differences between treatments in GFR declines
early after entering the study were nominally signif-
icant but not robust after adjustment. The addition or
dose adaptation of medications, such as amiodarone,
diuretics, or renin angiotensin blockers, could have
played a role or even direct hemodynamic or renal
effects of DE, which have not been investigated. In
addition, the more proximal inhibition of hemostasis
by VKAs involves factor VII antagonism, with poten-
tial beneﬁcial vascular effects, including plaque sta-
bilization. The importance of this (if any) and the
underlying mechanism are undetermined.
Interestingly, factor Xa and thrombin are associ-
ated with vascular inﬂammation involving the
thrombin receptor PAR2 (32). In another model of
inﬂammatory atherosclerosis, the thrombin inhibitors
DE (8) and melagatran (9) reduced vascular inﬂam-
mation, oxidative stress, and plaque load. Further-
more, increased calciﬁcations induced by inhibition
of the vitamin K–dependent protein matrix gamma-
carboxyglutamic acid (Gla/MGP) by warfarin (3,4)
might be involved in the calciﬁcation of renal ar-
teries (2) and increase plaque load and plaque
morphology (Central Illustration) (1,5). In agreement
with this hypothesis, patients with diabetes in the
present study had a more progressive decline in renal
function with warfarin compared with DE. Further-
more, the decline in renal function was more pro-
nounced in those patients with more vitamin K
CENTRAL ILLUSTRATION Vascular Calciﬁcation, Arterial Damage, and Decline in Renal Function May Be Triggered by the Inhibition of
the Vitamin K-Dependent Protein Matrix Gammacarboxyglutamic Acid (Gla/MGP) by Vitamin K Antagonists
Böhm, M. et al. J Am Coll Cardiol. 2015; 65(23):2481–93.
Decline in Renal Function
Via Inhibition of Bone
Morphogenetic Protein
(BMP-2 and BMP-4)
Matrix Gla protein (MGP) inhibits the osteoinductive function of bone morphogenetic protein (BMP). This function of MGP depends on gamma-carboxyglutamatic acid
residues, which are modiﬁed in a vitamin K–dependent manner. In addition to blocking gamma-carboxylation of coagulation factors, warfarin inhibits this function of
MGP, which in turn, antagonizes the inhibitory role of MGP in the process of vascular calciﬁcation, resulting in arterial damage and a decline in renal function.
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2491depletion under warfarin, demonstrated by an
increased INR out of the therapeutic range. This
ﬁnding was associated in previous studies with a
progressive decline in renal dysfunction (31), adding
plausibility to the hypothesis that the decline in renal
function is associated with VKA treatment. Mecha-
nistically, biopsy-proven episodic glomerular hem-
orrhage could play a role. Although renal functionseems to be differentially affected by DE and
warfarin, the efﬁcacy and safety of DE (33), as well as
other novel anticoagulants (34), in preventing stroke
were better or similar compared with warfarin.
Furthermore, previous impaired renal function is
associated with reoccurrence of AF (35). Thus,
changing the quality of AF by renal function also
could have had an effect on outcomes.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with nonvalvular AF, renal function declined
less during treatment with DE, 110 or 150 mg twice
daily, than in those randomized to receive warfarin.
This outcome may be due to inhibition by warfarin of
vitamin K–dependent matrix gamma-carboxyglutamic
acid (Gla/MPG).
TRANSLATIONAL OUTLOOK: Prospective trials
are needed to conﬁrm a potential advantage of
target-speciﬁc oral anticoagulants over warfarin with
respect to renal dysfunction during long-term treat-
ment and to establish the mechanism by which this
accrues.
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2492STUDY LIMITATIONS. The treatment duration of pa-
tients varied between 12 and 37 months, and thus the
comparisons at 24 and 30 months were based on a
subset of patients. The statistical model used in our
analysis accounts for these “structural” dropouts, and
the large study population ensures sufﬁcient statis-
tical power for reliable comparisons. The mean
treatment duration of w24 months was short
compared with the need for life-long anticoagulant
treatment to prevent thromboembolic events.
Therefore, the decline in renal function might be
underestimated in the present analysis compared
with long-term treatment in general practice. The
assumption of a deleterious effect of vitamin K
depletion over time is supported by the group of pa-
tients with previous VKA treatment who had a more
pronounced decline in estimated GFR with warfarin
compared with VKA-naive patients. Validation of
these results in a future study is warranted to conﬁrm
the deleterious effects of VKA treatment on renal
function.
CONCLUSIONS
In elderly patients with AF, there was a decline in
renal function that, at 30 months of follow-up, was
greater in patients treated with warfarin compared
with DE-treated patients and most pronounced in
patients with previous treatment with VKAs or in
patients with diabetes. The decline in renal function
with both treatments indicates the need for moni-
toring of renal function at regular intervals (e.g.,
once a year or more frequently in certain clinical
situations when it is suspected that the renalfunction could deteriorate) during oral anti-
coagulation treatment with warfarin as well as with
DE. The more rapid reduction in renal function dur-
ing warfarin treatment may be relevant in the selec-
tion of anticoagulants for long-term treatment.
Prospective validation of these results in future trials
is warranted.
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